Loading clinical trials...
Loading clinical trials...
Metastatic bone disease is an important prognostic factor for survival which will in median be close to two years after first diagnosis of osseous metastases. This open-label study will investigate th...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis Pharmaceuticals
NCT01840293 · Primary Breast Cancer, Recurrent/Metastatic Breast Cancer
NCT04622319 · HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
NCT06954532 · Cancer, Primary Breast Cancer
NCT05923177 · Primary Breast Cancer
NCT02214381 · Early Primary Breast Cancer
Novartis Invstigative Site
Bielefeld
Novartis Investigative Site
Hanover
Novartis Investigative Site
München
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions